+44 20 8123 2220
info@marketpublishers.com

Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter), Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)

https://marketpublishers.com/r/V6A64868934FEN.html
Date: April 2021
Pages: 295
Price: US$ 4,799.00 (Single User License)
ID: V6A64868934FEN

Abstracts

The vascular disrupting agents market is expected to reach USD 23 million in 2021 and anticipated to grow at a CAGR of 65% during the forecast period 2021-2030.

Solid tumors constitute roughly 90% of diagnosed cancer cases, driving extensive efforts towards developing innovative anticancer therapies tailored for these types of

cancers. Over the past five years, the United States Food and Drug Administration (USFDA) has approved over 100 drugs for diverse cancer treatments. Despite these advancements, the increasing global exposure to various carcinogens and risk factors necessitates the development of more targeted and potent drugs or therapies to effectively combat this complex and life-threatening disease. The rapid growth of malignant cell masses that characterize solid tumors emphasizes the critical role of angiogenesis and adequate blood supply in sustaining the tumor population. Consequently, targeting tumor vasculature remains a compelling and promising approach in therapeutic pursuits. Vascular disrupting agents (VDAs) are interventions aimed at established tumor vasculature, thereby disrupting blood flow to cancerous tissues.

Currently, several small molecule VDAs are either under development or have been developed to address various oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma, and ovarian cancer. Additionally, combination therapies that integrate VDAs with conventional chemotherapy, radiation therapy, and radioimmunotherapy have shown significant clinical responses in various animal models.

Significantly, the advancements in this field receive substantial support from the National Institutes of Health, with research grants totaling USD 95 million disbursed since 2016. Driven by promising clinical research outcomes, this specialized yet burgeoning domain is poised for robust market growth in the foreseeable future. Early entrants are expected to gain a competitive edge as pioneers in this evolving landscape.

Report Coverage

Examine the vascular disrupting agents market by categorizing it based on indications, therapeutic areas, molecules, therapy types, administration routes, and geographical regions.

Analyze market growth factors like drivers, restraints, opportunities, and challenges.

Evaluate potential market advantages and obstacles, focusing on the competitive landscape for leading players.

Forecast revenue for market segments across six major regions.

+44 20 8123 2220
info@marketpublishers.com

Assess the current landscape of vascular disrupting agents, detailing developmental stages of product candidates, therapeutic areas, molecule types, therapy types, and administration routes. Provide a comprehensive list of companies involved in this development, considering establishment year, company size, and headquarters location.

Present detailed profiles of prominent market players based on their pipeline volume, including company overview, financial information, lead drug candidates' descriptions, development status, indications, mode of action, therapy type, recent developments, and future forecasts.

Conduct an in-depth analysis of completed, ongoing, and planned clinical studies on vascular disrupting agents. Highlight trends in trial status, patient population, regional distribution, molecule types, developmental phases, study designs, leading industry and non-industry players, focus, and key indications.

Review over 750 peer-reviewed scientific articles on vascular disrupting agents published between 2016 and January 2021. Analyze trends in publication years, emerging focus areas, keywords, indications, therapeutic areas, research journals, and notable authors.

Analyze grants awarded to research institutes between 2016 and January 2021 related to vascular disrupting agents. Parameters include the year of award, amount, administering institute, support period, grant type, purpose, activity code, focus areas, popular departments, recipient organization types, highlighting popular recipients, program officers, and regional distribution.

Compile a list of key opinion leaders (KOLs) in the vascular disrupting agents market. Assess their prominence and activity using a 2x2 matrix representation. Create a world map indicating the locations of eminent scientists/researchers. Evaluate KOL expertise based on publications, citations, clinical trial participation, affiliations, and professional networks available on ResearchGate.

Key Market Companies

AGC Biologics

+44 20 8123 2220
info@marketpublishers.com

Avid Bioservices

Bionomics

Mateon Therapeutics

Myrexis

VBL Therapeutics

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

5. COMPANY PROFILES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter), Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)

Product link: https://marketpublishers.com/r/V6A64868934FEN.html

Price: US$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/V6A64868934FEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

+44 20 8123 2220
info@marketpublishers.com

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970